Keith C. Bible, M.D., Ph.D.
Oncologist
Sherman EJ, Harris J,
Bible KC
, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn GB, Foote RL, Yom SS, Wong SJ, Koyfman SA, Dzeda MF, Clump DA, Khan SA, Shah MH, Redmond K, Torres-Saavedra PA, Le QT, Lee NY. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. Lancet Oncol. 2023 Feb; 24 (2):175-186 Epub 2023 Jan 18
View PubMed
Shonka DC Jr, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Abdelhamid Ahmed AH,
Bible KC
, Brose MS, Cabanillas ME, Dabekaussen K, Davies L, Dias-Santagata D, Fagin JA, Faquin WC, Ghossein RA, Gopal RK, Miyauchi A, Nikiforov YE, Ringel MD, Robinson B, Ryder MM, Sherman EJ, Sadow PM, Shin JJ, Stack BC Jr, Tuttle RM, Wirth LJ, Zafereo ME Jr, Randolph GW. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022 Jun; 44 (6):1277-1300 Epub 2022 Mar 11
View PubMed
Hassan Nelson L, Fuentes-Bayne H, Yin J, Asmus E, Ryder M, Morris JC, Hilger CR,
Bible KC
, Chintakuntlawar AV, Rao SN. Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. J Endocr Soc. 2022 May 1; 6 (5):bvac044 Epub 2022 Mar 22
View PubMed
Gao RW, Foote RL, Garces YI, Ma DJ, Neben-Wittich M, Routman DM, Patel SH, Ko SJ, McGee LA,
Bible KC
, Chintakuntlawar AV, Ryder M, Morris JC, Van Abel KM, Rivera M, Abraha F, Lester SC. Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy. Pract Radiat Oncol. 2022 Mar-Apr; 12 (2):113-119 Epub 2021 Oct 26
View PubMed
Bible KC
. Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned. AACE Clin Case Rep. 2021 Sep-Oct; 7 (5):334-335 Epub 2021 Mar 20
View PubMed
Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI,
Bible KC
, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021 Jul 20; 39 (21):2359-2366 Epub 2021 May 07
View PubMed
Ho AL, Brana I, Haddad R, Bauman J,
Bible K
, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Jun 10; 39 (17):1856-1864 Epub 2021 Mar 22
View PubMed
Bible KC
, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021 Mar; 31 (3):337-386
View PubMed
Bruce JY,
Bible KC
, Chintakuntlawar AV. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. Thyroid 2021 Feb; 31 (2):332-333 Epub 2020 Aug 04
View PubMed
Bible KC
, Menefee ME, Lin CC, Millward MJ, Maples WJ, Goh BC, Karlin NJ, Kane MA, Adkins DR, Molina JR, Donehower RC, Lim WT, Flynn PJ, Richardson RL, Traynor AM, Rubin J, LoRusso PM, Smallridge RC, Burton JK, Suman VJ, Kumar A, Voss JS, Rumilla KM, Kipp BR, Chintakuntlawar AV, Harris P, Erlichman C. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid. 2020 Sep; 30 (9):1254-1262 Epub 2020 July 29
View PubMed
Miller KC, Chintakuntlawar AV, Hilger C, Bancos I, Morris JC, Ryder M, Smith CY, Jenkins SM,
Bible KC
. Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. J Endocr Soc. 2020 Jul 1; 4 (7):bvaa069 Epub 2020 June 09
View PubMed
Iniguez-Ariza NM, Jasim S, Ryder MM, Chintakuntlawar AV, Morris JC, Hilger CR, Menefee ME, Smallridge RC, Karlin NJ, Alcaino C,
Bible KC
. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. J Clin Endocrinol Metab. 2020 Jul 1; 105 (7)
View PubMed
Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB, Campbell M,
Bible KC
, Ryder M, Chintakuntlawar AV, Habra MA. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer. 2020 Jul; 8 (2)
View PubMed
Iniguez-Ariza NM,
Bible KC
, Clarke BL. Bone metastases in thyroid cancer. J Bone Oncol. 2020 Apr; 21:100282 Epub 2020 Feb 19
View PubMed
Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces Y, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC 3rd, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E,
Bible KC
. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 2019 Nov; 29 (11):1615-1622
View PubMed
Xie H, Yin J, Shah MH, Menefee ME,
Bible KC
, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 Aug; 37 (4):755-762 Epub 2019 June 06
View PubMed
Chintakuntlawar AV, Foote RL, Kasperbauer JL,
Bible KC
. Diagnosis and Management of Anaplastic Thyroid Cancer. Endocrinol Metab Clin North Am. 2019 Mar; 48 (1):269-284
View PubMed
Luster M, Aktolun C, Amendoeira I, Barczynski M,
Bible KC
, Duntas LH, Elisei R, Handkiewicz-Junak D, Hoffmann M, Jarzab B, Leenhardt L, Musholt TJ, Newbold K, Nixon IJ, Smit J, Sobrinho-Simoes M, Sosa JA, Tuttle RM, Verburg FA, Wartofsky L, Fuhrer D. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019 Jan; 29 (1):7-26 Epub 2019 Jan 07
View PubMed
Brose MS,
Bible KC
, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev. 2018 May; 66:64-73 Epub 2018 Apr 22
View PubMed
Iniguez-Ariza NM, Stan MN,
Bible KC
. Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. Endocrine. 2018 Jan; 59 (1):228-229 Epub 2017 Nov 01
View PubMed
Breen W, Bancos I, Young WF Jr,
Bible KC
, Laack NN, Foote RL, Hallemeier CL. External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol. 2018 Jan-Mar; 3 (1):25-29 Epub 2017 Nov 22
View PubMed
Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Neben Wittich MA, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC,
Bible KC
. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017 Dec 1; 102 (12):4506-4514
View PubMed
Jasim S, Iniguez-Ariza NM, Hilger CR, Chintakuntlawar AV, Ryder MM, Morris JC 3rd,
Bible KC
. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS. Endocr Pract. 2017 Aug 17;
View PubMed
Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ,
Bible KC
. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017 Aug; 57 (2):220-225 Epub 2017 July 06
View PubMed
Iniguez-Ariza NM, Ryder MM, Hilger CR,
Bible KC
. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid. 2017 Jul; 27 (7):923-927 Epub 2017 May 31
View PubMed
Jasim S, Nathan MA,
Bible KC
. "Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. Endocrine. 2017 Jul; 57 (1):187-188 Epub 2017 May 16
View PubMed
French JD,
Bible K
, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017 Jun; 5 (6):469-481 Epub 2016 Oct 20
View PubMed
Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ,
Bible KC
, Que FG, Nagorney DM, Young WF, Thompson GB. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. Ann Surg Oncol. 2017 Jun; 24 (6):1546-1550 Epub 2017 Jan 05
View PubMed
Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C,
Bible KC
. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab. 2017 Jun 01; 102(6):1943-1950.
View PubMed
Haugen BR, Sawka AM, Alexander EK,
Bible KC
, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 Apr; 27 (4):481-483 Epub 2017 Feb 21
View PubMed
Jasim S, Chintakuntlawar A,
Bible KC
. Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma International Journal Of Endocrine Oncology. 2016 Nov; 3: (4)285-9.
Bible KC
, Ryder M. Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncol 2016 Sep; 17 (9):1181-3 Epub 2016 July 23
View PubMed
Bible KC
, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016 Jul; 13 (7):403-16 Epub 2016 Mar 01
View PubMed
Bible KC
, Chintakuntlawar AV, Ryder M. Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. J Oncol Pract 2016 Jun; 12 (6):521-2
View PubMed
Spitzweg C, Morris JC,
Bible KC
. New drugs for medullary thyroid cancer: new promises? Endocr Relat Cancer. 2016 Jun; 23: (6)R287-97.
View PubMed
Rosenthal MS, Angelos P,
Bible K
, Fassler CA, Finder S, Greene LW, Tulchinsky M. Informed consent for low-risk thyroid cancer International Journal Of Endocrine Oncology. 2016 May; 3: (2)131-42.
Haugen BR, Alexander EK,
Bible KC
, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26 (1):1-133
View PubMed
Bible KC
, Cote GJ, Demeure MJ, Elisei R, Jhiang S, Ringel MD, International Thyroid Oncology Group Correlative Science Committee. Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. J Clin Endocrinol Metab. 2015 Dec; 100 (12):4387-95 Epub 2015 Sept 29
View PubMed
Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS, Evans DB, Grubbs EG,
Bible KC
, Young WF, Perrier ND, Que FG, Nagorney DM, Lee JE, Thompson GB. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015 Jan; 22 (1):146-51 Epub 2014 Aug 05
View PubMed
Spitzweg C,
Bible KC
, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014 Oct; 2 (10):830-42 Epub 2014 June 02
View PubMed
Isham CR, Netzel BC, Bossou AR, Milosevic D, Cradic KW, Grebe SK,
Bible KC
. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors. J Clin Endocrinol Metab. 2014 Jun; 99 (6):E936-43 Epub 2014 Mar 14
View PubMed
Bible KC
, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014 May; 99 (5):1687-93 Epub 2014 Feb 25
View PubMed
Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW,
Bible KC
, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014 Feb; 10 (2):e1004135 Epub 2014 Feb 13
View PubMed
Dy BM, Wise KB, Richards ML, Young WF Jr, Grant CS,
Bible KC
, Rosedahl J, Harmsen WS, Farley DR, Thompson GB. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013 Dec; 154(6):1292-9; discussion 1299.
View PubMed
Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN,
Bible KC
, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31 (5):1201-6 Epub 2013 July 26
View PubMed
Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME,
Bible KC
, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013 Jun; 98 (6):2392-400 Epub 2013 Apr 15
View PubMed
Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA,
Bible KC
. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013 Jan 2; 5 (166):166ra3
View PubMed
Smallridge RC, Ain KB, Asa SL,
Bible KC
, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM, American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov; 22 (11):1104-39
View PubMed
Bible KC
, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C, Mayo Phase 2 Consortium (P2C)//North Central Cancer Treatment Group (NCCTG). A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol. 2012 Oct; 127 (1):55-62 Epub 2012 June 01
View PubMed
Bible KC
, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C, Mayo Phase 2 Consortium//Mayo Clinic Endocrine Malignances Disease Oriented Group. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012 Sep; 97 (9):3179-84 Epub 2012 July 06
View PubMed
Bible KC
, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. J Oncol Pract. 2012 May; 8 (3 Suppl):e1s-5s
View PubMed
Bible KC
, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C. Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. Am J Manag Care. 2012 May 1; 18 (5):e162-7 Epub 2012 May 01
View PubMed
Isham CR, Tibodeau JD, Bossou AR, Merchan JR,
Bible KC
. The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation. Br J Cancer. 2012 Jan 17; 106 (2):314-23 Epub 2011 Dec 20
View PubMed
Menefee ME, Smallridge RC,
Bible KC
. Systemic therapeutic approaches to advanced thyroid cancers. Am Soc Clin Oncol Educ Book. 2012; 389-92
View PubMed
Reddi HV, Madde P, Cohen YC, Bangio L, Breitbart E, Harats D,
Bible KC
, Eberhardt NL. Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models. Genes Cancer. 2011 Oct; 2 (10):993-5
View PubMed
Harris PJ,
Bible KC
. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011 Oct; 20(10):1357-75.
View PubMed
Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC,
Bible KC
. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011 Jan; 21 (1):25-30 Epub 2010 Dec 16
View PubMed
Bible KC
, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group//Mayo Clinic Cancer Center//Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct; 11 (10):962-72 Epub 2010 Sept 17
View PubMed
Tibodeau JD, Isham CR,
Bible KC
. Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductase. Antioxid Redox Signal. 2010 Oct 1; 13 (7):987-97
View PubMed
Sideras K, Menefee ME, Burton JK, Erlichman C,
Bible KC
, Ivy SP. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol. 2010 Jul 1; 28 (19):e312-3 Epub 2010 June 01
View PubMed
Tibodeau JD, Benson LM, Isham CR, Owen WG,
Bible KC
. The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal. 2009 May; 11 (5):1097-106
View PubMed
Heath EI,
Bible K
, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs. 2008 Feb; 26(1):59-65. Epub 2007 Oct 16.
View PubMed
Pizarro GO, Zhou XC, Koch A, Gharib M, Raval S,
Bible K
, Jones MB. Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse. Int J Cancer. 2007 Jun 1; 120 (11):2339-43
View PubMed
Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P,
Bible KC
, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, Kaufmann SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem. 2007 Mar 23; 282 (12):8860-72 Epub 2007 Jan 09
View PubMed
Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM,
Bible KC
. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood. 2007 Mar 15; 109 (6):2579-88 Epub 2006 Nov 07
View PubMed
Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK,
Bible KC
, Hartmann LC, Kaufmann SH, Shridhar V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 2006 Jul; 116 (7):1994-2004 Epub 2006 June 08
View PubMed
Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C,
Bible KC
. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica. 2006 Mar; 91(3):390-3. Epub 2006 Feb 17.
View PubMed
Lee YK, Isham CR, Kaufman SH,
Bible KC
. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther. 2006 Jan; 5 (1):138-48
View PubMed
Karp JE, Passaniti A, Gojo I, Kaufmann S,
Bible K
, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005 Dec 1; 11(23):8403-12.
View PubMed
Bible KC
, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res. 2005 Aug 15; 11 (16):5935-41
View PubMed
Fatima J, Gipson JC, Farnell MB,
Bible KC
. Is this really a duodenal adenocarcinoma? What is this mass and why should a surgeon be involved? Contemp Surg. 2005 Aug; 61(8):393-397.
Boerner SA, Tourne ME, Kaufmann SH,
Bible KC
. Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer. 2001 May 18; 84 (10):1391-6
View PubMed
Shridhar V,
Bible KC
, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DI. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001 May 15; 61 (10):4258-65
View PubMed
Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD,
Bible KC
, Kaufmann SH. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001 Jan 15; 61 (2):739-48
View PubMed
Bible KC
, Bible RH Jr, Kottke TJ, Svingen PA, Xu K, Pang YP, Hajdu E, Kaufmann SH. Flavopiridol binds to duplex DNA. Cancer Res. 2000 May 1; 60 (9):2419-28
View PubMed
Bible KC
, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res. 2000 Feb; 6 (2):661-70
View PubMed
Mesner PW Jr,
Bible KC
, Martins LM, Kottke TJ, Srinivasula SM, Svingen PA, Chilcote TJ, Basi GS, Tung JS, Krajewski S, Reed JC, Alnemri ES, Earnshaw WC, Kaufmann SH. Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile. J Biol Chem. 1999 Aug 6; 274 (32):22635-45
View PubMed
Bible KC
, Boerner SA, Kaufmann SH. A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid. Anal Biochem. 1999 Feb 1; 267(1):217-21.
View PubMed
Bible KC
, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997 Aug 15; 57(16):3375-80.
View PubMed
Bible KC
, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1996 Nov 1; 56 (21):4856-61
View PubMed
Sings HL,
Bible KC
, Rinehart KL. Acyl tunichlorins: a new class of nickel chlorins isolated from the Caribbean tunicate Trididemnum solidum. Proc Natl Acad Sci U S A. 1996 Oct 1; 93(20):10560-5.
View PubMed
Bible KC
, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol. 1996 May; 93 (2):406-8
View PubMed
Bible KC
, Buytendorp M, Zierath PD, Rinehart KL. Tunichlorin: a nickel chlorin isolated from the Caribbean tunicate Trididemnum solidum. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4582-6.
View PubMed
Rinehart KL, Kishore V,
Bible KC
, Sakai R, Sullins DW, Li KM. Didemnins and tunichlorin: novel natural products from the marine tunicate Trididemnum solidum. J Nat Prod. 1988 Jan-Feb; 51(1):1-21.
View PubMed
Bible KC
, Nelson RA, et al. Renal function in hospitalized patients receiving intravenous infusions of amino acids. Carle Sel Pap. 1986 Fall; 38:27-33.
Bible KC
, Hatfield AK, Lansford CL, Kammer BA. Gastric ulceration as a complication of hepatic artery infusion chemotherapy. South Med J. 1986 Jun; 79(6):755-7.
View PubMed
Witte DL, Persoon TJ,
Bible K
, Routh JI. Choice of reference sera for measurement of effective thyroxine ratio. J Nucl Med Technol. 1978; 6:69-72.
.
Mayo Clinic Footer